# Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations

> **NCT03316560** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Beacon Therapeutics** · enrollment: 29 (actual)

## Conditions studied

- X-Linked Retinitis Pigmentosa

## Interventions

- **BIOLOGICAL:** rAAV2tYF-GRK1-RPGR

## Key facts

- **NCT ID:** NCT03316560
- **Lead sponsor:** Beacon Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-04-16
- **Primary completion:** 2023-11-09
- **Final completion:** 2025-03
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2024-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03316560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03316560, "Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT03316560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*